resTORbio Announces Science Translational Medicine Publication of Phase 2a Data Showing Improvement in Immune Function and Decreased Infection Rates in People Aged 65 Years and Older

World News: . []

BOSTON July 11 2018 GLOBE NEWSWIRE -- resTORbio NasdaqTORC today announced newly published data from a Phase 2a clinical trial demonstrating that target of rapamycin complex 1 TORC1 inhibitor treatment improved immune function and decreas ed inci...

More news and information about resTORbio, Inc.

Published By:

Globe Newswire: 19:07 GMT Wednesday 11th July 2018

Published: .

Search for other references to "restorbio" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2018. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
 
Privacy Policy | Terms and Conditions | Contact Us